Home › Companies › SPRB

SPRUCE BIOSCIENCES, INC.

SPRB Rare disease Lead: Preclinical 1 Biotech Distilled article ↓

Metabolic Neurology Protein Small Molecule

Most recent annual filing: 2026-03-09

Pipeline (2 active programs)

tralesinidase alfa

TA-ERT

Protein Target: NAGLU, rhNAGLU

Mucopolysaccharidosis Type IIIB intracerebroventricular

SPR202

Protein Target: CRF, CRH

Congenital Adrenal Hyperplasia Preclinical HBM Alpha Therapeutics, Inc.

Discontinued (1)

tildacerfont — Major Depressive Disorder · serious adverse event — significant elevation of liver enzymes in a patient

Biotech Distilled coverage (1)

2026-05-08 Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.